SunTrust Banks Initiates Coverage on Fate Therapeutics (NASDAQ:FATE)
SunTrust Banks began coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research note released on Tuesday, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $25.00 price target on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on the stock. Cantor Fitzgerald initiated coverage on shares […]
SunTrust Banks Initiates Coverage on Fate Therapeutics (NASDAQ:FATE)
SunTrust Banks began coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a research note released on Tuesday, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $25.00 price target on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on the stock. Cantor Fitzgerald initiated coverage on shares […]